chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 77.0
Sex: F
Vaccine: COVID19
Symptoms: Body height, Injection site erythema, Pruritus, Vaccination site warmth, Weight
Clinical narrative: warm around the part of the arm that is itching; left arm started itching; red around the vaccination area; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 77 year-old female patient received bnt162b2 (BNT162B2), intramuscular, administered in arm left, administration date 24Sep2021 10:30 (Lot number: EW0175) at the age of 77 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Heart issues" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (1st dose), administration date: 02Feb2021, for COVID-19 Immunization; Bnt162b2 (2nd dose), administration date: 23Feb2021, for COVID-19 Immunization.  The following information was reported: PRURITUS (non-serious) with onset 26Sep2021, outcome "not recovered", described as "left arm started itching"; INJECTION SITE ERYTHEMA (non-serious) with onset 26Sep2021, outcome "unknown", described as "red around the vaccination area"; VACCINATION SITE WARMTH (non-serious), outcome "not recovered", described as "warm around the part of the arm that is itching". Relevant laboratory tests and procedures are available in the appropriate section.  Follow up (12Oct2021): This is a follow up spontaneous report from a contactable consumer. This consumer (Receptionist) reported in response to HCP telephonic follow up activity which included that:   Phone Out 2:02 PM, 1St attempt by phone to HCP to obtain mailing information. Phone out to HCP. Phone answered by receptionist (name not provided) who provided physician's mailing address and full name.  Follow-Up (18Oct2021): Follow-up attempts are completed. No further information is expected.
Age: 35.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Chest pain, Electrocardiogram, Investigation, Ultrasound scan
Clinical narrative: having pain in his left shoulder blade; pain in his left shoulder blade and into his chest; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  A 36 year-old male patient received bnt162b2 (BNT162B2), administration date 12Sep2021 (Lot number: FC3182) at the age of 35 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "Hypertension" (unspecified if ongoing), notes: controlled it with medication. Concomitant medication(s) included: VITAMIN C [ASCORBIC ACID]; VITAMIN D NOS. The following information was reported: ARTHRALGIA (non-serious), outcome "unknown", described as "having pain in his left shoulder blade"; CHEST PAIN (non-serious), outcome "unknown", described as "pain in his left shoulder blade and into his chest". The events "having pain in his left shoulder blade" and "pain in his left shoulder blade and into his chest" were evaluated at the emergency room visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of arthralgia, chest pain.  Additional information: The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient did not receive any treatment for the events.  No follow-up attempts are possible. No further information is expected.
Age: 35.0
Sex: M
Vaccine: COVID19
Symptoms: X-ray
Clinical narrative: having pain in his left shoulder blade; pain in his left shoulder blade and into his chest; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  A 36 year-old male patient received bnt162b2 (BNT162B2), administration date 12Sep2021 (Lot number: FC3182) at the age of 35 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "Hypertension" (unspecified if ongoing), notes: controlled it with medication. Concomitant medication(s) included: VITAMIN C [ASCORBIC ACID]; VITAMIN D NOS. The following information was reported: ARTHRALGIA (non-serious), outcome "unknown", described as "having pain in his left shoulder blade"; CHEST PAIN (non-serious), outcome "unknown", described as "pain in his left shoulder blade and into his chest". The events "having pain in his left shoulder blade" and "pain in his left shoulder blade and into his chest" were evaluated at the emergency room visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of arthralgia, chest pain.  Additional information: The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient did not receive any treatment for the events.  No follow-up attempts are possible. No further information is expected.
Sex: M
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: Low grade fever; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the parent.  A 12 year-old male patient received bnt162b2 (BNT162B2), administration date 26Sep2021 (Lot number: FF2588) as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (It's the same number for the first and the second FF2588), for COVID-19 Immunization.  The following information was reported: PYREXIA (non-serious), outcome "unknown", described as "Low grade fever".  No follow-up attempts are possible. No further information is expected.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Burning sensation, Disturbance in attention, Ear pain, Head discomfort, Headache
Clinical narrative: unable to focus; headache; onset of burning; sore throat; bilateral ear pain; head congestion; lethargy; body aches; 9/10 fever/9/11 fever; This is a spontaneous report received from contactable reporter(s) (Other HCP). The reporter is the patient.  A 49 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), intramuscular, administered in arm right, administration date 10Sep2021 11:00 (Lot number: FC3181) at the age of 49 years as dose 2, single for covid-19 immunisation. The patient had no relevant medical history. Concomitant medication(s) included: LEXAPRO; VITAMIN C [ASCORBIC ACID]; VITAMIN D [COLECALCIFEROL]. Past drug history included: Ceclor, reaction(s): "Allergy:CECLOR"; Keflex, reaction(s): "Allergy: KEFLEX"; Biaxin, reaction(s): "Allergy:BIAXIN"; Percocet, reaction(s): "Allergy:PERCOCET". Vaccination history included: Bnt162b2 (lot number: EW0173, administrator route: Intramuscular, administration time: 14:00, dose number: 1, vaccine location: Right arm), administration date: 20Aug2021, when the patient was 49 years old, for COVID-19 Immunization. The following information was reported: DISTURBANCE IN ATTENTION (non-serious) with onset 13Sep2021, outcome "recovering", described as "unable to focus"; PAIN (non-serious) with onset 11Sep2021, outcome "recovering", described as "body aches"; BURNING SENSATION (non-serious) with onset 12Sep2021, outcome "recovering", described as "onset of burning"; OROPHARYNGEAL PAIN (non-serious) with onset 12Sep2021, outcome "recovering", described as "sore throat"; EAR PAIN (non-serious) with onset 12Sep2021, outcome "recovering", described as "bilateral ear pain"; HEAD DISCOMFORT (non-serious) with onset 12Sep2021, outcome "recovering", described as "head congestion"; LETHARGY (non-serious) with onset 11Sep2021, outcome "recovering", described as "lethargy"; HEADACHE (non-serious) with onset 13Sep2021, outcome "recovering", described as "headache"; PYREXIA (non-serious) with onset 10Sep2021 17:00, outcome "recovering", described as "9/10 fever/9/11 fever". The events "unable to focus", "body aches", "onset of burning", "sore throat", "bilateral ear pain", "head congestion", "lethargy", "headache" and "9/10 fever/9/11 fever" were evaluated at the physician office visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of disturbance in attention, pain, burning sensation, oropharyngeal pain, ear pain, head discomfort, lethargy, headache, pyrexia.  Additional information: The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient received MV within 2 weeks of vaccination. Treatment received for the adverse event was with steroids. Prior to vaccination, the patient was not diagnosed with COVID-19.  Follow-up attempts are completed. No further information is expected.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Lethargy, Oropharyngeal pain, Pain, Pyrexia, SARS-CoV-2 test
Clinical narrative: unable to focus; headache; onset of burning; sore throat; bilateral ear pain; head congestion; lethargy; body aches; 9/10 fever/9/11 fever; This is a spontaneous report received from contactable reporter(s) (Other HCP). The reporter is the patient.  A 49 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), intramuscular, administered in arm right, administration date 10Sep2021 11:00 (Lot number: FC3181) at the age of 49 years as dose 2, single for covid-19 immunisation. The patient had no relevant medical history. Concomitant medication(s) included: LEXAPRO; VITAMIN C [ASCORBIC ACID]; VITAMIN D [COLECALCIFEROL]. Past drug history included: Ceclor, reaction(s): "Allergy:CECLOR"; Keflex, reaction(s): "Allergy: KEFLEX"; Biaxin, reaction(s): "Allergy:BIAXIN"; Percocet, reaction(s): "Allergy:PERCOCET". Vaccination history included: Bnt162b2 (lot number: EW0173, administrator route: Intramuscular, administration time: 14:00, dose number: 1, vaccine location: Right arm), administration date: 20Aug2021, when the patient was 49 years old, for COVID-19 Immunization. The following information was reported: DISTURBANCE IN ATTENTION (non-serious) with onset 13Sep2021, outcome "recovering", described as "unable to focus"; PAIN (non-serious) with onset 11Sep2021, outcome "recovering", described as "body aches"; BURNING SENSATION (non-serious) with onset 12Sep2021, outcome "recovering", described as "onset of burning"; OROPHARYNGEAL PAIN (non-serious) with onset 12Sep2021, outcome "recovering", described as "sore throat"; EAR PAIN (non-serious) with onset 12Sep2021, outcome "recovering", described as "bilateral ear pain"; HEAD DISCOMFORT (non-serious) with onset 12Sep2021, outcome "recovering", described as "head congestion"; LETHARGY (non-serious) with onset 11Sep2021, outcome "recovering", described as "lethargy"; HEADACHE (non-serious) with onset 13Sep2021, outcome "recovering", described as "headache"; PYREXIA (non-serious) with onset 10Sep2021 17:00, outcome "recovering", described as "9/10 fever/9/11 fever". The events "unable to focus", "body aches", "onset of burning", "sore throat", "bilateral ear pain", "head congestion", "lethargy", "headache" and "9/10 fever/9/11 fever" were evaluated at the physician office visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of disturbance in attention, pain, burning sensation, oropharyngeal pain, ear pain, head discomfort, lethargy, headache, pyrexia.  Additional information: The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient received MV within 2 weeks of vaccination. Treatment received for the adverse event was with steroids. Prior to vaccination, the patient was not diagnosed with COVID-19.  Follow-up attempts are completed. No further information is expected.
Age: 35.0
Sex: M
Vaccine: COVID19
Symptoms: Axillary pain, Chest pain
Clinical narrative: left armpit/chest pain, kind of where the lymph nodes are; left armpit/chest pain , kind of where the lymph nodes are; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 35 year-old male patient received bnt162b2 (BNT162B2), administered in arm right, administration date 31Aug2021 16:30 (Lot number: fd8448) at the age of 35 years as dose 1, single and administered in arm right, administration date 20Sep2021 16:30 (Lot number: fd8448) as dose 2, single for covid-19 immunisation. The patient had no relevant medical history. The patient's concomitant medications were not reported. The following information was reported: CHEST PAIN (non-serious) with onset Sep2021, outcome "not recovered", described as "left armpit/chest pain, kind of where the lymph nodes are"; AXILLARY PAIN (non-serious) with onset Sep2021, outcome "not recovered", described as "left armpit/chest pain , kind of where the lymph nodes are". Therapeutic measures were not taken as a result of chest pain, axillary pain.  Additional information: The patient did not have covid prior vaccination. The patient did not get covid tested post vaccination. The patient had no known allergies. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient reported left armpit/chest pain, kind of where the lymph nodes are. Almost constant, goes away when he squeeze or apply pressure in that area.  No follow-up attempts are possible. No further information is expected.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Poor quality sleep
Clinical narrative: Sore aching joints; bad enough to interrumpt my sleep; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 70 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm right, administration date 27Sep2021 16:30 (Lot number: 3015BA) at the age of 70 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "High chloresteral" (unspecified if ongoing). Concomitant medication(s) included: BUSPIRONE; ROSUVASTATIN. The following information was reported: ARTHRALGIA (non-serious), outcome "recovering", described as "Sore aching joints"; POOR QUALITY SLEEP (non-serious), outcome "recovering", described as "bad enough to interrumpt my sleep". Therapeutic measures were not taken as a result of arthralgia, poor quality sleep.  Additional information: Prior to vaccination, patient was diagnosed with COVID since the vaccination, patient has been tested for COVID. no treatment received.  Follow-Up (12Oct2021): Follow-up attempts are completed. No further information is expected.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Myalgia, Pyrexia
Clinical narrative: fever; muscle aches; headaches; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 68 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 26Sep2021 12:00 (Lot number: FF8835) at the age of 68 years as dose number unknown, single for covid-19 immunisation. Relevant medical history included: "diabetes" (unspecified if ongoing). Concomitant medication(s) included: METFORMIN. The following information was reported: PYREXIA (non-serious) with onset 27Sep2021 12:00, outcome "unknown", described as "fever"; MYALGIA (non-serious) with onset 27Sep2021 12:00, outcome "unknown", described as "muscle aches"; HEADACHE (non-serious) with onset 27Sep2021 12:00, outcome "unknown", described as "headaches". Therapeutic measures were not taken as a result of pyrexia, myalgia, headache.  Additional information: The most recent COVID-19 vaccine was administered at Pharmacy or Drug Store. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient received metformin within 2 weeks of vaccination. Adverse event did not require a visit to Emergency Room/Physician Office. The patient did not receive any treatment for the events. No prolonged hospitalization was reported. Prior to vaccination, the patient was not diagnosed with COVID-19; Since the vaccination, the patient has not been tested for COVID-19.  No follow-up attempts are possible. No further information is expected.
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Cough, Erythema, Pruritus, Respiration abnormal, Throat clearing
Clinical narrative: itching over her right breast/itching had spread over her chest, back and throat; itching over her right breast/itching had spread over her chest, back and throat; itching over her right breast/itching had spread over her chest, back and throat; 3inch in diameter erythema on the right breast; breathing was louder; clearing her throat; coughing; This is a spontaneous report received from a non-contactable reporter(s) (Pharmacist).  A 38 year-old female patient received bnt162b2 (BNT162B2), intramuscular, administered in arm right, administration date 24Sep2021 (Lot number: EW0162) at the age of 38 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "if covid prior vaccination: Yes" (unspecified if ongoing), notes: if covid prior vaccination: Yes. The patient's concomitant medications were not reported.  The following information was reported: PRURITUS (non-serious), THROAT IRRITATION (non-serious), PRURITUS (non-serious) all with onset 24Sep2021, outcome "unknown" and all described as "itching over her right breast/itching had spread over her chest, back and throat"; ERYTHEMA (non-serious) with onset 24Sep2021, outcome "unknown", described as "3inch in diameter erythema on the right breast"; RESPIRATION ABNORMAL (non-serious) with onset 24Sep2021, outcome "unknown", described as "breathing was louder"; THROAT CLEARING (non-serious) with onset 24Sep2021, outcome "unknown", described as "clearing her throat"; COUGH (non-serious) with onset 24Sep2021, outcome "unknown", described as "coughing". The events "itching over her right breast/itching had spread over her chest, back and throat", "itching over her right breast/itching had spread over her chest, back and throat", "itching over her right breast/itching had spread over her chest, back and throat", "3inch in diameter erythema on the right breast", "breathing was louder", "clearing her throat" and "coughing" were evaluated at the emergency room visit. Therapeutic measures were taken as a result of pruritus, throat irritation, pruritus, erythema. It was unknown if therapeutic measures were taken as a result of respiration abnormal, throat clearing, cough.  Additional information: Immediately after receiving the vaccine the patient reported itching over her right breast. The pharmacist visualized a 3inch in diameter erythema on the right breast. The patient denied changes in breathing or any difficulty in breathing. Benadryl 25mg PO was given. 27 minutes after the Benadryl was given the patients breathing was louder and the itching had spread over her chest, back, and throat. The patient was clearing her throat with coughing. The patient then reported to the ER.  No follow-up attempts are possible. No further information is expected.
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Throat irritation
Clinical narrative: itching over her right breast/itching had spread over her chest, back and throat; itching over her right breast/itching had spread over her chest, back and throat; itching over her right breast/itching had spread over her chest, back and throat; 3inch in diameter erythema on the right breast; breathing was louder; clearing her throat; coughing; This is a spontaneous report received from a non-contactable reporter(s) (Pharmacist).  A 38 year-old female patient received bnt162b2 (BNT162B2), intramuscular, administered in arm right, administration date 24Sep2021 (Lot number: EW0162) at the age of 38 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "if covid prior vaccination: Yes" (unspecified if ongoing), notes: if covid prior vaccination: Yes. The patient's concomitant medications were not reported.  The following information was reported: PRURITUS (non-serious), THROAT IRRITATION (non-serious), PRURITUS (non-serious) all with onset 24Sep2021, outcome "unknown" and all described as "itching over her right breast/itching had spread over her chest, back and throat"; ERYTHEMA (non-serious) with onset 24Sep2021, outcome "unknown", described as "3inch in diameter erythema on the right breast"; RESPIRATION ABNORMAL (non-serious) with onset 24Sep2021, outcome "unknown", described as "breathing was louder"; THROAT CLEARING (non-serious) with onset 24Sep2021, outcome "unknown", described as "clearing her throat"; COUGH (non-serious) with onset 24Sep2021, outcome "unknown", described as "coughing". The events "itching over her right breast/itching had spread over her chest, back and throat", "itching over her right breast/itching had spread over her chest, back and throat", "itching over her right breast/itching had spread over her chest, back and throat", "3inch in diameter erythema on the right breast", "breathing was louder", "clearing her throat" and "coughing" were evaluated at the emergency room visit. Therapeutic measures were taken as a result of pruritus, throat irritation, pruritus, erythema. It was unknown if therapeutic measures were taken as a result of respiration abnormal, throat clearing, cough.  Additional information: Immediately after receiving the vaccine the patient reported itching over her right breast. The pharmacist visualized a 3inch in diameter erythema on the right breast. The patient denied changes in breathing or any difficulty in breathing. Benadryl 25mg PO was given. 27 minutes after the Benadryl was given the patients breathing was louder and the itching had spread over her chest, back, and throat. The patient was clearing her throat with coughing. The patient then reported to the ER.  No follow-up attempts are possible. No further information is expected.
Sex: F
Vaccine: COVID19
Symptoms: Hypersensitivity, Rash macular
Clinical narrative: Allergic reaction; she got brown spots all over her feet; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the parent.  A 12 year-old female patient (unknown if pregnant) received bnt162b2 (BNT162B2), administration date 26Sep2021 (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: HYPERSENSITIVITY (non-serious) with onset Sep2021, outcome "unknown", described as "Allergic reaction"; RASH MACULAR (non-serious) with onset Sep2021, outcome "unknown", described as "she got brown spots all over her feet". The events "allergic reaction" and "she got brown spots all over her feet" were evaluated at the emergency room visit.  Additional information: Reported that, 12 years old, took the shot yesterday (as reported) and she got an allergic reaction out of it. Reporter's daughter got the shot and she got brown spots all over her feet and are in the emergency room right now (at the time of report); she has several big brown spots on her feet. Reporter asking for somebody who can help them with this and wanted to know what was going on. The side effects of the Covid, reporter mean vaccine for Pfizer for children (Later reporter confirmed the suspect as Covid vaccine for Pfizer). Reporter was also advised to consult with her daughter's healthcare provider.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Dizziness, Fatigue, Migraine, Pruritus
Clinical narrative: migraine; fatigue; light headed; chills; fever; constant itch below my ankle; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non-HCP). The reporter is the patient. This case is for her 2nd dose.  A 36-year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date Sep2021 (Lot number: FC3184) at the age of 36 years as dose 2, single for covid-19 immunization. The patient's relevant medical history was not reported. There were no concomitant medications. Vaccination history included: Bnt162b2 (Lot number: FF2589, first dose, Left arm), for COVID-19 immunization, reaction(s): "bad nightmares". The following information was reported: MIGRAINE (non-serious) with onset Sep2021, outcome "recovering", described as "migraine"; FATIGUE (non-serious) with onset Sep2021, outcome "recovering", described as "fatigue"; DIZZINESS (non-serious) with onset Sep2021, outcome "recovering", described as "light headed"; CHILLS (non-serious) with onset Sep2021, outcome "recovering", described as "chills"; PYREXIA (non-serious) with onset Sep2021, outcome "recovering", described as "fever"; PRURITUS (non-serious) with onset Sep2021, outcome "recovering", described as "constant itch below my ankle". Therapeutic measures were not taken as a result of migraine, fatigue, dizziness, chills, pyrexia, pruritus.  Additional information: The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient did not receive other medications the patient received within 2 weeks of vaccination. The patient neither diagnosed with COVID-19 Prior to vaccination, nor been tested for COVID-19 Since the vaccination. No known allergies.  No follow-up attempts are possible. No further information is expected.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: migraine; fatigue; light headed; chills; fever; constant itch below my ankle; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non-HCP). The reporter is the patient. This case is for her 2nd dose.  A 36-year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date Sep2021 (Lot number: FC3184) at the age of 36 years as dose 2, single for covid-19 immunization. The patient's relevant medical history was not reported. There were no concomitant medications. Vaccination history included: Bnt162b2 (Lot number: FF2589, first dose, Left arm), for COVID-19 immunization, reaction(s): "bad nightmares". The following information was reported: MIGRAINE (non-serious) with onset Sep2021, outcome "recovering", described as "migraine"; FATIGUE (non-serious) with onset Sep2021, outcome "recovering", described as "fatigue"; DIZZINESS (non-serious) with onset Sep2021, outcome "recovering", described as "light headed"; CHILLS (non-serious) with onset Sep2021, outcome "recovering", described as "chills"; PYREXIA (non-serious) with onset Sep2021, outcome "recovering", described as "fever"; PRURITUS (non-serious) with onset Sep2021, outcome "recovering", described as "constant itch below my ankle". Therapeutic measures were not taken as a result of migraine, fatigue, dizziness, chills, pyrexia, pruritus.  Additional information: The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient did not receive other medications the patient received within 2 weeks of vaccination. The patient neither diagnosed with COVID-19 Prior to vaccination, nor been tested for COVID-19 Since the vaccination. No known allergies.  No follow-up attempts are possible. No further information is expected.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Chest pain
Clinical narrative: having chest pain; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 25 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 16Sep2021 10:15 (Lot number: 30135BA) at the age of 25 years as dose 2, single for Covid-19 immunisation. Relevant medical history included: "COVID-19" (unspecified if ongoing), notes: Prior to vaccination, was the patient diagnosed with COVID-19: Yes. Concomitant medication(s) included: Citalopram; Buspar; Cardizem [Diltiazem Hydrochloride]; Prenatal Plus; Vitamin D [Colecalciferol]; B12 [Cyanocobalamin]. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE, Lot number: EW0183, vaccine location=Left arm, administration time=10:00), administration date: 26Aug2021, when the patient was 25 years old, for Covid-19 Immunization. The following information was reported: CHEST PAIN (non-serious) with onset 19Sep2021 04:30, outcome "not recovered", described as "having chest pain". The event "having chest pain" was evaluated at the emergency room visit. Therapeutic measures were not taken as a result of chest pain. Additional information: The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient started having chest pain on 19Sep2021. It was a sharp pain that lasted 5 seconds then a dull pain that has continued. Since the vaccination, the patient has not been tested for COVID-19. No follow-up attempts are possible. No further information is expected.
Age: 57.0
Sex: M
Vaccine: COVID19
Symptoms: Blood pressure measurement, Body temperature, Body temperature increased, Decreased appetite, Heart rate
Clinical narrative: blood pressure it's 126/88, pulse 99, and temperature 98.9, which is 3 points above normal/Had always had a really low pulse and wants to know whether this is normal or not; blood pressure it's 126/88, pulse 99, and temperature 98.9, which is 3 points above normal; blood pressure it's 126/88, pulse 99, and temperature 98.9, which is 3 points above normal; didn't eat his breakfast like he usually does; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the parent.  A 57 year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 27Sep2021 13:00 (Lot number: FF2588) at the age of 57 years as dose 3 (booster), 0.3 ml single for covid-19 immunisation. Relevant medical history included: "galactosemia" (unspecified if ongoing); "a liver disease" (unspecified if ongoing); "immune system is compromised" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose 1, lot number: EL9261), administration date: 15Jan2021, when the patient was 56 years old, for Covid-19 immunization; Bnt162b2 (Dose 2, lot number: EL9265), administration date: 05Feb2021, when the patient was 56 years old, for Covid-19 immunization. The following information was reported: HEART RATE INCREASED (non-serious) with onset 28Sep2021, outcome "not recovered", described as "blood pressure it's 126/88, pulse 99, and temperature 98.9, which is 3 points above normal/Had always had a really low pulse and wants to know whether this is normal or not"; BODY TEMPERATURE INCREASED (non-serious), HYPERTENSION (non-serious) all with onset 28Sep2021, outcome "not recovered" and all described as "blood pressure it's 126/88, pulse 99, and temperature 98.9, which is 3 points above normal"; DECREASED APPETITE (non-serious) with onset 28Sep2021, outcome "not recovered", described as "didn't eat his breakfast like he usually does". Relevant laboratory tests and procedures are available in the appropriate section.  Additional information: History of all previous immunization with the Pfizer vaccine considered as suspect were none. Additional vaccines administered on same date of the pfizer suspect were none. The events did not require emergency room or physician office visit. Prior Vaccinations (within 4 weeks) were none. AE(s) following prior vaccinations were none. Family medical history relevant to ae(s): none. No problems with shots in past.   No follow-up attempts are possible. No further information is expected.
Age: 57.0
Sex: M
Vaccine: COVID19
Symptoms: Heart rate increased, Hypertension
Clinical narrative: blood pressure it's 126/88, pulse 99, and temperature 98.9, which is 3 points above normal/Had always had a really low pulse and wants to know whether this is normal or not; blood pressure it's 126/88, pulse 99, and temperature 98.9, which is 3 points above normal; blood pressure it's 126/88, pulse 99, and temperature 98.9, which is 3 points above normal; didn't eat his breakfast like he usually does; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the parent.  A 57 year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 27Sep2021 13:00 (Lot number: FF2588) at the age of 57 years as dose 3 (booster), 0.3 ml single for covid-19 immunisation. Relevant medical history included: "galactosemia" (unspecified if ongoing); "a liver disease" (unspecified if ongoing); "immune system is compromised" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose 1, lot number: EL9261), administration date: 15Jan2021, when the patient was 56 years old, for Covid-19 immunization; Bnt162b2 (Dose 2, lot number: EL9265), administration date: 05Feb2021, when the patient was 56 years old, for Covid-19 immunization. The following information was reported: HEART RATE INCREASED (non-serious) with onset 28Sep2021, outcome "not recovered", described as "blood pressure it's 126/88, pulse 99, and temperature 98.9, which is 3 points above normal/Had always had a really low pulse and wants to know whether this is normal or not"; BODY TEMPERATURE INCREASED (non-serious), HYPERTENSION (non-serious) all with onset 28Sep2021, outcome "not recovered" and all described as "blood pressure it's 126/88, pulse 99, and temperature 98.9, which is 3 points above normal"; DECREASED APPETITE (non-serious) with onset 28Sep2021, outcome "not recovered", described as "didn't eat his breakfast like he usually does". Relevant laboratory tests and procedures are available in the appropriate section.  Additional information: History of all previous immunization with the Pfizer vaccine considered as suspect were none. Additional vaccines administered on same date of the pfizer suspect were none. The events did not require emergency room or physician office visit. Prior Vaccinations (within 4 weeks) were none. AE(s) following prior vaccinations were none. Family medical history relevant to ae(s): none. No problems with shots in past.   No follow-up attempts are possible. No further information is expected.
Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Bedridden, Body temperature, Illness, Movement disorder, Pain
Clinical narrative: a fever of 103F; sick; in bed for 3 days; ached; couldn't move; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 75 year-old female patient received bnt162b2 (BNT162B2), administered in arm right, administration date 11Feb2021 (Lot number: EL9267) at the age of 75 years as dose 2, single for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. Vaccination history included: Bnt162b2 (first dose- 21Jan2021, given in right arm around 10:30-11am, Lot EL3249), administration date: 21Jan2021, when the patient was 75 years old, for COVID-19 immunization, reaction(s): "sore arm", "Red Arm". The following information was reported: PYREXIA (non-serious) with onset Feb2021, outcome "recovered" (Feb2021), described as "a fever of 103F"; ILLNESS (non-serious) with onset Feb2021, outcome "recovered" (Feb2021), described as "sick"; BEDRIDDEN (non-serious) with onset Feb2021, outcome "recovered" (Feb2021), described as "in bed for 3 days"; PAIN (non-serious) with onset Feb2021, outcome "recovered" (Feb2021), described as "ached"; MOVEMENT DISORDER (non-serious) with onset Feb2021, outcome "recovered" (Feb2021), described as "couldn't move". Relevant laboratory tests and procedures are available in the appropriate section.  No follow-up attempts are possible. No further information is expected.
Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: a fever of 103F; sick; in bed for 3 days; ached; couldn't move; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 75 year-old female patient received bnt162b2 (BNT162B2), administered in arm right, administration date 11Feb2021 (Lot number: EL9267) at the age of 75 years as dose 2, single for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. Vaccination history included: Bnt162b2 (first dose- 21Jan2021, given in right arm around 10:30-11am, Lot EL3249), administration date: 21Jan2021, when the patient was 75 years old, for COVID-19 immunization, reaction(s): "sore arm", "Red Arm". The following information was reported: PYREXIA (non-serious) with onset Feb2021, outcome "recovered" (Feb2021), described as "a fever of 103F"; ILLNESS (non-serious) with onset Feb2021, outcome "recovered" (Feb2021), described as "sick"; BEDRIDDEN (non-serious) with onset Feb2021, outcome "recovered" (Feb2021), described as "in bed for 3 days"; PAIN (non-serious) with onset Feb2021, outcome "recovered" (Feb2021), described as "ached"; MOVEMENT DISORDER (non-serious) with onset Feb2021, outcome "recovered" (Feb2021), described as "couldn't move". Relevant laboratory tests and procedures are available in the appropriate section.  No follow-up attempts are possible. No further information is expected.
Age: 53.0
Sex: U
Vaccine: COVID19, COVID19
Symptoms: Arthralgia, Bone pain, Fatigue, Malaise, Vaccination site pain
Clinical narrative: Joint pain; Bone pain; Pain at the injection site; Fatigue; Malaise; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from a sales representative. The reporter is the patient.  A 53 year-old patient received bnt162b2 (BNT162B2), intramuscular, administered in arm left, administration date 26Sep2021 16:00 (Lot number: FF8839) at the age of 53 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "colon cancer", start date: Jul2017, stop date: Oct2017, notes: Pertinent details: complete colectomy; "Broken ankle", start date: Feb2016, stop date: Feb2016, notes: Pertinent details: Ankle reconstruction; "Cholecystectomy", start date: Aug2016, stop date: Aug2016, notes: Pertinent details: Cholecystectomy; "Gall bladder", start date: Aug2016, stop date: Aug2016, notes: Pertinent details: Cholecystectomy; "Hysterectomy", start date: Aug2001, stop date: Aug2001, notes: Pertinent details: Hysterectomy Prolapsed in delivery. Concomitant medication(s) included: LEXAPRO taken for anxiety (ongoing); OXYBUTYNIN taken for incontinence (ongoing). Vaccination history included: Bnt162b2 (Dose Number:01, Time: 9:00 AM, Anatomical site of injection: Left arm , Route of administration: Intramuscular, Batch/Lot number: Pfizer EL9267), administration date: 13Feb2021, for Covid-19 Immunization; Bnt162b2 (Dose Number:02, Time: 9:00 AM, Anatomical site of injection: Left arm, Route of administration: Intramuscular, Batch/Lot number: Pfizer EN6205), administration date: 06Mar2021, for Covid-19 Immunization. The following information was reported: VACCINATION SITE PAIN (non-serious) with onset Sep2021, outcome "recovered" (Sep2021), described as "Pain at the injection site"; FATIGUE (non-serious) with onset Sep2021, outcome "recovered" (Sep2021), described as "Fatigue"; MALAISE (non-serious) with onset Sep2021, outcome "recovered" (Sep2021), described as "Malaise"; ARTHRALGIA (non-serious) with onset 28Sep2021, outcome "recovered" (30Sep2021), described as "Joint pain"; BONE PAIN (non-serious) with onset 28Sep2021, outcome "recovered" (30Sep2021), described as "Bone pain". Therapeutic measures were taken as a result of vaccination site pain, fatigue, malaise, arthralgia, bone pain.  Additional information: Simply treated with over-the-counter reaction painkillers, ice, and heat. The pain would have caused me to seek medical treatment if the patient did not know the inciting incident. The pain lasted only 36 hours. Vaccine facility type was Pharmacy or drug store. No prior vaccinations were administered. Lexapro was started from 17Oct and Oxybutynin from 01Oct and ongoing and Advil from 26Sep to 01Oct. The patient received Advil as treatment for the event. Relevant tests were reported as none.  No follow-up attempts are possible. No further information is expected.
Age: 53.0
Sex: U
Vaccine: COVID19, COVID19
Symptoms: Fatigue, Lethargy, Loss of personal independence in daily activities, Malaise, Myalgia
Clinical narrative: Joint pain; Bone pain; Pain at the injection site; Fatigue; Malaise; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from a sales representative. The reporter is the patient.  A 53 year-old patient received bnt162b2 (BNT162B2), intramuscular, administered in arm left, administration date 26Sep2021 16:00 (Lot number: FF8839) at the age of 53 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "colon cancer", start date: Jul2017, stop date: Oct2017, notes: Pertinent details: complete colectomy; "Broken ankle", start date: Feb2016, stop date: Feb2016, notes: Pertinent details: Ankle reconstruction; "Cholecystectomy", start date: Aug2016, stop date: Aug2016, notes: Pertinent details: Cholecystectomy; "Gall bladder", start date: Aug2016, stop date: Aug2016, notes: Pertinent details: Cholecystectomy; "Hysterectomy", start date: Aug2001, stop date: Aug2001, notes: Pertinent details: Hysterectomy Prolapsed in delivery. Concomitant medication(s) included: LEXAPRO taken for anxiety (ongoing); OXYBUTYNIN taken for incontinence (ongoing). Vaccination history included: Bnt162b2 (Dose Number:01, Time: 9:00 AM, Anatomical site of injection: Left arm , Route of administration: Intramuscular, Batch/Lot number: Pfizer EL9267), administration date: 13Feb2021, for Covid-19 Immunization; Bnt162b2 (Dose Number:02, Time: 9:00 AM, Anatomical site of injection: Left arm, Route of administration: Intramuscular, Batch/Lot number: Pfizer EN6205), administration date: 06Mar2021, for Covid-19 Immunization. The following information was reported: VACCINATION SITE PAIN (non-serious) with onset Sep2021, outcome "recovered" (Sep2021), described as "Pain at the injection site"; FATIGUE (non-serious) with onset Sep2021, outcome "recovered" (Sep2021), described as "Fatigue"; MALAISE (non-serious) with onset Sep2021, outcome "recovered" (Sep2021), described as "Malaise"; ARTHRALGIA (non-serious) with onset 28Sep2021, outcome "recovered" (30Sep2021), described as "Joint pain"; BONE PAIN (non-serious) with onset 28Sep2021, outcome "recovered" (30Sep2021), described as "Bone pain". Therapeutic measures were taken as a result of vaccination site pain, fatigue, malaise, arthralgia, bone pain.  Additional information: Simply treated with over-the-counter reaction painkillers, ice, and heat. The pain would have caused me to seek medical treatment if the patient did not know the inciting incident. The pain lasted only 36 hours. Vaccine facility type was Pharmacy or drug store. No prior vaccinations were administered. Lexapro was started from 17Oct and Oxybutynin from 01Oct and ongoing and Advil from 26Sep to 01Oct. The patient received Advil as treatment for the event. Relevant tests were reported as none.  No follow-up attempts are possible. No further information is expected.
Age: 53.0
Sex: U
Vaccine: COVID19, COVID19
Symptoms: Pain in extremity
Clinical narrative: Joint pain; Bone pain; Pain at the injection site; Fatigue; Malaise; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from a sales representative. The reporter is the patient.  A 53 year-old patient received bnt162b2 (BNT162B2), intramuscular, administered in arm left, administration date 26Sep2021 16:00 (Lot number: FF8839) at the age of 53 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "colon cancer", start date: Jul2017, stop date: Oct2017, notes: Pertinent details: complete colectomy; "Broken ankle", start date: Feb2016, stop date: Feb2016, notes: Pertinent details: Ankle reconstruction; "Cholecystectomy", start date: Aug2016, stop date: Aug2016, notes: Pertinent details: Cholecystectomy; "Gall bladder", start date: Aug2016, stop date: Aug2016, notes: Pertinent details: Cholecystectomy; "Hysterectomy", start date: Aug2001, stop date: Aug2001, notes: Pertinent details: Hysterectomy Prolapsed in delivery. Concomitant medication(s) included: LEXAPRO taken for anxiety (ongoing); OXYBUTYNIN taken for incontinence (ongoing). Vaccination history included: Bnt162b2 (Dose Number:01, Time: 9:00 AM, Anatomical site of injection: Left arm , Route of administration: Intramuscular, Batch/Lot number: Pfizer EL9267), administration date: 13Feb2021, for Covid-19 Immunization; Bnt162b2 (Dose Number:02, Time: 9:00 AM, Anatomical site of injection: Left arm, Route of administration: Intramuscular, Batch/Lot number: Pfizer EN6205), administration date: 06Mar2021, for Covid-19 Immunization. The following information was reported: VACCINATION SITE PAIN (non-serious) with onset Sep2021, outcome "recovered" (Sep2021), described as "Pain at the injection site"; FATIGUE (non-serious) with onset Sep2021, outcome "recovered" (Sep2021), described as "Fatigue"; MALAISE (non-serious) with onset Sep2021, outcome "recovered" (Sep2021), described as "Malaise"; ARTHRALGIA (non-serious) with onset 28Sep2021, outcome "recovered" (30Sep2021), described as "Joint pain"; BONE PAIN (non-serious) with onset 28Sep2021, outcome "recovered" (30Sep2021), described as "Bone pain". Therapeutic measures were taken as a result of vaccination site pain, fatigue, malaise, arthralgia, bone pain.  Additional information: Simply treated with over-the-counter reaction painkillers, ice, and heat. The pain would have caused me to seek medical treatment if the patient did not know the inciting incident. The pain lasted only 36 hours. Vaccine facility type was Pharmacy or drug store. No prior vaccinations were administered. Lexapro was started from 17Oct and Oxybutynin from 01Oct and ongoing and Advil from 26Sep to 01Oct. The patient received Advil as treatment for the event. Relevant tests were reported as none.  No follow-up attempts are possible. No further information is expected.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration, Urticaria
Clinical narrative: Inappropriate schedule of vaccine administered; Hives on chest and shoulders; This is a spontaneous report received from contactable reporter(s) (Other HCP). The reporter is the patient.  A 33 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), intramuscular, administered in arm right, administration date 09Sep2021 08:00 (Lot number: Fc3183) at the age of 33 years as dose 2, single for covid-19 immunisation. The patient's relevant medical history was not reported. There were no concomitant medications. Past drug history included: Allergies: cephalexin, reaction(s): "Allergies: Cephalexin", notes: Allergies: Cephalexin. Vaccination history included: Bnt162b2 (1st dose, lot number=Ew0164,, Administrator route=Intramuscular,, Administration time=08:00 AM,, vaccine location=Right arm), administration date: 24Aug2021, when the patient was 33 years old, for Covid-19 Immunization. The following information was reported: INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (non-serious) with onset 28Sep2021, outcome "unknown", described as "Inappropriate schedule of vaccine administered"; URTICARIA (non-serious) with onset 28Sep2021, outcome "recovered" (2021), described as "Hives on chest and shoulders". Therapeutic measures were not taken as a result of inappropriate schedule of product administration, urticaria.  Additional information: The events were assessed as non-serious, did not result in death, not life threatening, did not cause/prolonged hospitalization, not disabling/incapacitating, did not cause congenital anomaly/birth defect. Treatment was not received for the adverse events. The patient has not received any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19.   Follow-up attempts are completed. No further information is expected.